"LogP 6.5. Too high."
Mikhail sighed.
"But the activity is really high!" Sena countered.
"If it doesn't reach the body, it's meaningless."
Lina displayed a graph. Relationship between LogP and oral absorption.
"Look. Above LogP 5, absorption rate drops sharply."
"Why? Isn't dissolving in fat good?"
"Moderately, yes," Mikhail explained. "But too lipophilic causes problems."
"First, solubility," Lina supplemented. "Becomes water-insoluble. Won't dissolve in digestive tract."
"Can't be absorbed if it doesn't dissolve."
Sena understood. "Dissolution is the first step."
"Yes. But that's not all," Mikhail continued. "There's also permeability issues."
"What? High lipophilicity makes membrane crossing easier, right?"
"To a point. But too high, and it gets stuck in the membrane."
Lina displayed a model. Cell membrane cross-section. Lipid bilayer.
"Molecule enters membrane. But to exit the other side, must return to aqueous phase."
"Too hydrophobic, can't return to water."
"Stuck in membrane," Mikhail said.
"That means..."
"Not absorbed, or extremely slow."
Sena looked at the structure. "What should we do?"
"Increase polarity. But while maintaining activity," Mikhail presented the challenge.
"Sounds difficult..."
"The core of drug design."
Lina proposed candidates. "Add hydroxy group at this position?"
"Impact on activity?"
"Calculation shows 10% reduction."
"LogP?"
"Decreases 1.2. Becomes 5.3."
Mikhail evaluated. "Good direction. But still high."
"Add polar group at another position?" Sena proposed.
"Where?"
"Here. Part extending outside pocket."
Lina modeled. "Change to amide bond. LogP 4.1."
"That's within range," Mikhail nodded.
"But," Sena worried. "Is activity okay?"
"Won't know without trying. But this position should have small impact."
Lina pointed out another issue. "Lowering LogP might speed up metabolism."
"What?"
"Higher polarity increases hepatic clearance," Mikhail explained.
"Why?"
"Uptake into hepatocytes increases. Becomes easier substrate for transporters."
Sena was confused. "So what should we do?"
"Balance," Mikhail emphasized. "LogP 2-4 is ideal. Neither too low nor too high."
Lina displayed data. "LogP distribution of approved drugs. Most in 1-5 range."
"Around 3 is most common."
"This range balances solubility and permeability well."
Sena calculated. "So LogP 4.1 is good?"
"Passable," Mikhail evaluated. "But actual solubility measurement is important."
"Calculation alone insufficient?"
"LogP is organic solvent/water partition. Different from in vivo."
Lina supplemented. "pH, protein binding, micelle formation. Complex factors."
"So we experiment."
Sena asked. "Other problems with too high hydrophobicity?"
"Toxicity," Mikhail answered seriously. "Easily causes non-specific membrane damage."
"Embeds in lipid membranes and disrupts structure."
"That leads to cytotoxicity."
"hERG inhibition too," Lina added. "Cause of cardiotoxicity."
"Hydrophobic cations bind hERG channel easily."
Mikhail organized. "The hydrophobic trap. Attractive but has pitfalls."
"Higher activity compounds tend to be more hydrophobic."
"But to make them drugs, need to add polarity."
Sena resolved. "Then I'll create revised proposals."
"Aim for LogP 3-4 while maintaining activity."
Mikhail encouraged. "Difficult, but possible. Many drugs have walked this path."
Lina said finally. "Hydrophobicity and hydrophilicity. Walking that tightrope is drug discovery."
Sena gazed at the structure. The hydrophobic trap. But understanding it means avoiding it. Finding balance. That's the next challenge.
"I'll calculate," Lina opened her laptop.
"I'll think about structures," Sena took out her notebook.
Finding the way out of the hydrophobic trap. That was today's battle.